ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSAGet Free Report) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 193,500 shares, an increase of 545.0% from the January 15th total of 30,000 shares. Approximately 1.5% of the shares of the company are sold short. Based on an average trading volume of 880,200 shares, the days-to-cover ratio is presently 0.2 days.

ZyVersa Therapeutics Price Performance

ZVSA stock opened at $0.57 on Tuesday. The business’s 50-day moving average is $0.81 and its two-hundred day moving average is $3.10. ZyVersa Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $96.95.

ZyVersa Therapeutics (NASDAQ:ZVSAGet Free Report) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($3.15) earnings per share for the quarter, topping the consensus estimate of ($5.60) by $2.45. Equities research analysts forecast that ZyVersa Therapeutics will post -86.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Walleye Capital LLC purchased a new position in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSAFree Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned approximately 3.17% of ZyVersa Therapeutics as of its most recent SEC filing. Institutional investors own 36.69% of the company’s stock.

About ZyVersa Therapeutics

(Get Free Report)

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.

Featured Stories

Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.